Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Total Non-Current Liabilities (2016 - 2017)

Cytosorbents' Total Non-Current Liabilities history spans 5 years, with the latest figure at $13.1 million for Q2 2017.

  • Quarterly results put Total Non-Current Liabilities at $13.1 million for Q2 2017, up 87.33% from a year ago — trailing twelve months through Jun 2017 was $13.1 million (up 87.33% YoY), and the annual figure for FY2016 was $6.5 million, up 364.95%.
  • Total Non-Current Liabilities for Q2 2017 was $13.1 million at Cytosorbents, up from $8.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $13.1 million in Q2 2017 to a low of -$1.5 million in Q4 2014.
  • The 4-year median for Total Non-Current Liabilities is $6.8 million (2016), against an average of $5.5 million.
  • Peak annual rise in Total Non-Current Liabilities hit 402.59% in 2017, while the deepest fall reached 87.33% in 2017.
  • Year by year, Total Non-Current Liabilities stood at -$1.5 million in 2014, then surged by 196.59% to $1.4 million in 2015, then soared by 364.95% to $6.5 million in 2016, then skyrocketed by 100.53% to $13.1 million in 2017.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $13.1 million, $8.2 million, and $6.5 million for Q2 2017, Q1 2017, and Q4 2016 respectively.